INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors
FibroGen, Inc (FGEN)
Last fibrogen, inc earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-irhome
Company Research
Source: Business Wire
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of FibroGen, Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers’ possible violations of federal securities laws.On November 4, 2019, Plainview LLC (“Plainview”) published a report questioning the safety and efficacy of Fibrogen’s lead product candidate, Roxadustat.On this news, Fibrogen’s stock price fell $3.01 per share, or nearly 8%, to close at $37.01 per share on November 4, 2019, thereby injuring investors.If you purchased FibroGen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howards
Show less
Read more
Impact Snapshot
Event Time:
FGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FGEN alerts
High impacting FibroGen, Inc news events
Weekly update
A roundup of the hottest topics
FGEN
News
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology AAcquire Media Monitor
- FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology GlobeNewswire
- Pancreatic Cancer Pipeline Market Research 2024: Comprehensive Insights on More than 290 Companies and their Associated 300+ Pipeline Drugs [Yahoo! Finance]Yahoo! Finance
- Kind Pharmaceuticals Announces Settlement [Yahoo! Finance]Yahoo! Finance
- FibroGen falls after early-stage data for prostate cancer drug [Seeking Alpha]Seeking Alpha
FGEN
Earnings
- 2/26/24 - Miss
FGEN
Sec Filings
- 4/25/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- FGEN's page on the SEC website